ArticleBMC clinical pathology2012
Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer.
Article in BMC clinical pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The Role of MMP8 in Cancer: A Systematic Review.International journal of molecular sciences · 2019Pooled it
- Review
- Comparative analysis of matrix metalloproteinases by zymography in patients with colorectal carcinoma.Physiological research · 2023Article
- Predictive Significance of Two MMP-9 Promoter Polymorphisms and Acetylated c-Jun Transcription Factor for Papillary Thyroid Carcinoma Advancement.Diagnostics (Basel, Switzerland) · 2022Article
- Flavonoid GL-V9 suppresses invasion and migration of human colorectal cancer cells by inhibiting PI3K/Akt and MMP-2/9 signaling.Journal of Cancer · 2021Article
- Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.BMC cancer · 2018Article
- Expression profile of NF-κB regulated genes in sporadic colorectal cancer patients.Oncology letters · 2018Article
- Immunohistochemical analysis reveals variations in proteasome tissue expression in C. elegans.PloS one · 2017Article
- Human cytomegalovirus-encoded US28 may act as a tumor promoter in colorectal cancer.World journal of gastroenterology · 2016Article
- Baicalein inhibits the migration and invasion of colorectal cancer cells via suppression of the AKT signaling pathway.Oncology letters · 2016Article
- Impact of high glucose on metastasis of colon cancer cells.World journal of gastroenterology · 2015Article
- The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials.Frontiers in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelled
backgroundMatrix metalloproteinases (MMPs) play a role in cancer progression by degrading extracellular matrix and basement membranes, assisting in tumour neovascularization and in supporting immune response in cancer.
methodsWe studied the prognostic value of immunohistochemical expression of MMP-2, MMP-8, and MMP-9 in a series of 619 colorectal cancer patients using tissue microarray specimens.
resultsOf the samples, 56% were positive for MMP-2, 78% for MMP-8, and 60% for MMP-9. MMP-9 associated with low WHO grade (p < 0.001). In univariate analysis of Dukes' B tumours, MMP-9 negativity associated with poor survival (p = 0.018), and MMP-9 positivity was an independent prognostic marker in multivariate analysis of these tumours (p = 0.034).
conclusionNegative MMP-9 expression can predict poor prognosis in Dukes' B colorectal tumours and may prove useful for identifying patients, who should be offered adjuvant treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.